Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:08 PM
Ignite Modification Date:
2025-12-24 @ 10:08 PM
NCT ID:
NCT02468635
Eligibility Criteria:
Inclusion Criteria:
* Patients with COPD eligible to moderate COPD according to the criteria of gold GOLD (Global Initiative for Chronic Obstructive Lung Disease) and who had post-bronchodilator spirometry results in the last year of FEV1 (forced expiratory volume in one second) / FVC (forced vital capacity) \<0.7 and FEV1 between 50% and 80% of previsto.
* Besides being former smokers for at least three months and were clinically stable, no disease exacerbation in the past three months.
* Accompanied by a pulmonologist.
* Age between 40-85 years.
* They are not practicing physical activity.
* Without cardiovascular or orthopedic disease that makes it impossible to perform the exercises of the RP protocol.
* Without presenting other comorbidities that put them at risk during the exercises .
* Use of bronchodilators and oral theophylline, oxygen therapy or corticosteroids.
Exclusion Criteria:
* Patients who have musculoskeletal comorbidities that interfere with walking or performing upper extremity exercises.
* lower peripheral saturation decrease of oxygen lower than 90% during the 6 minute walk test (six) minutes.
* Presenting difficulty of cognitive understanding of body awareness and the ability to recall information for the questionnaire responses applied in the evaluation and re-evaluation in addition to this also children, adolescents and legally incapable
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Maximum Age:
85 Years
Study:
NCT02468635
Study Brief:
Protocol Section:
NCT02468635